Abstract
Spinal muscular atrophy (SMA) (5q) is an autosomal recessive neurodegenerative neuromuscular condition. SMA is associated with a high rate of mortalities and morbidities. Scoliosis is one of the common morbidities associated with this condition. Nusinersen is a relatively new treatment for SMA patients. A lot is unknown about the long-term effect of nusinersen. To document the development and progression of scoliosis in SMA-type I treated with nusinersen. In this retrospective study, patients with SMA-type I, treated with nusinersen were enrolled.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
